Literature DB >> 10494444

Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine: effect of alpha 2-adrenoceptor blockade.

L Linnér1, L Arborelius, G G Nomikos, L Bertilsson, T H Svensson.   

Abstract

BACKGROUND: Previous studies indicate a reduced feedback inhibition of brain noradrenaline (NA) neurons in the locus coeruleus (LC) during chronic administration of antidepressants which inhibit the NA reuptake mechanism due to functional downregulation of somatodendritic alpha 2-adrenoceptors in the LC. Therefore, we have here studied the LC neuronal responsiveness to administration of the alpha 2-adrenoceptor antagonist idazoxan (IDA) after both short-term and long-term imipramine (IMI) administration.
METHODS: Rats were treated for different periods with systemic IMI. In these rats, basal activity of central noradrenergic function and the effect of IDA was assessed by means of extracellular single-cell recording from LC neurons and in vivo microdialysis of extracellular NA levels in the frontal cortex (FC).
RESULTS: The average firing rate of LC neurons was significantly reduced in rats by short-term IMI treatment compared with long-term treatment. The output of NA in the FC of all IMI-treated animals was significantly increased compared with saline-treated rats. Moreover, the enhancing effect of IDA on both the firing rate of LC neurons and the cortical NA output was larger in rats after long-term treatment with IMI than after short-term administration.
CONCLUSIONS: Our results clearly support the notion of development of functional downregulation of alpha 2-autoreceptors on LC neurons during chronic administration of NA reuptake inhibiting antidepressants. Moreover, the data suggest that addition of alpha 2-adrenoceptor antagonists may augment the clinical effect of such drugs in major depression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494444     DOI: 10.1016/s0006-3223(99)00126-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  12 in total

1.  Desipramine selectively potentiates norepinephrine-elicited ERK1/2 activation through the α2A adrenergic receptor.

Authors:  Christopher Cottingham; Adrian Jones; Qin Wang
Journal:  Biochem Biophys Res Commun       Date:  2012-03-03       Impact factor: 3.575

2.  Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome.

Authors:  V Morgan; D Pickens; S Gautam; R Kessler; H Mertz
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

3.  Acute and chronic effects of desipramine and clorgyline on alpha(2)-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study.

Authors:  Y Mateo; B Fernández-Pastor; J J Meana
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.

Authors:  Kinga Kamińska; Tomasz Lenda; Jolanta Konieczny; Elżbieta Lorenc-Koci
Journal:  Psychopharmacology (Berl)       Date:  2022-09-30       Impact factor: 4.415

5.  Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons.

Authors:  Charles H K West; James C Ritchie; Katherine A Boss-Williams; Jay M Weiss
Journal:  Int J Neuropsychopharmacol       Date:  2008-10-27       Impact factor: 5.176

6.  Postsynaptic alpha-2 adrenergic receptors are critical for the antidepressant-like effects of desipramine on behavior.

Authors:  Han-Ting Zhang; Lisa R Whisler; Ying Huang; Yang Xiang; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

Review 7.  α2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy.

Authors:  Christopher Cottingham; Qin Wang
Journal:  Neurosci Biobehav Rev       Date:  2012-08-13       Impact factor: 8.989

8.  Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3).

Authors:  John J Mooney; Jacqueline A Samson; John Hennen; Kathleen Pappalardo; Nancy McHale; Jonathan Alpert; Martha Koutsos; Joseph J Schildkraut
Journal:  J Psychiatr Res       Date:  2007-08-28       Impact factor: 4.791

9.  A randomized controlled trial of imipramine in patients with irritable bowel syndrome.

Authors:  Heitham Abdul-Baki; Ihab I El Hajj; Lara Elzahabi; Cecilio Azar; Elie Aoun; Assaad Skoury; Hani Chaar; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

10.  Associations of a regulatory polymorphism of monoamine oxidase-A gene promoter (MAOA-uVNTR) with symptoms of depression and sleep quality.

Authors:  Beverly H Brummett; Andrew D Krystal; Ilene C Siegler; Cynthia Kuhn; Richard S Surwit; Stephan Züchner; Allison Ashley-Koch; John C Barefoot; Redford B Williams
Journal:  Psychosom Med       Date:  2007-06       Impact factor: 4.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.